trial

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

NCTId NCT01052103
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 167 (actual)
Sponsored by Denovo Biopharma LLC
Primary completion 2012-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
167 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2010-01
Primary completion
2012-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Pomaglumetad

Sponsors

Denovo Biopharma LLCLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

9 total
Garden Grove, United StatesChicago, United StatesHoffman Estates, United StatesNew York, United StatesJerusalem, IsraelParma, ItalyTorino, ItalyBarcelona, SpainZamora, Spain

Linked catalysts

1
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms — primary completion2012-06

Facts & assertions

4 sourced
Enrollment
167
Phase
PHASE2
Primary Completion Date
2012-06
Status
COMPLETED
relationships
The graph out of here
drug
Pomaglumetad
drug
lead_sponsor
Denovo Biopharma LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person